A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib)
The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Exclusion Criteria:
Capital Federal, Buenos Aires C1264AAA, Argentina
Salvador - Ba, Estado de Bahia 40050-410, Brazil
Kashiwa-shi, Chiba 2778577, Japan
Ogaki-shi, Gifu 5038502, Japan
Higashinari-ku, Osaka 5378511, Japan
Osaka-sayama-shi, Osaka 5898511, Japan
Sunto-gun, Shizuoka 4118777, Japan
Bunkyo-ku, Tokyo 1138655, Japan
Chuo-ku, Tokyo 104-0045, Japan
Musashino-shi, Tokyo 1808610, Japan
Shimonoseki-shi, Yamaguchi 7500061, Japan
Nishinomiya-shi, 6638501, Japan
D.f., Mexico City 14140, Mexico
Taoyuan Hsien, 333, Taiwan